Trial lifecycle: from protocol to label

The sequence is the same for a small academic study and a global phase 3, differing only in scale. It begins with a question and a protocol, with the statistical analysis plan alongside. The sponsor seeks authorisation to use the investigational product (an investigational new drug application in the United States, a clinical trial application in Europe and the United Kingdom) and submits the protocol and consent materials to ethics review. The trial is registered publicly before the first participant is enrolled. Sites are selected, contracted, trained and activated, which for a multinational phase 3 is the slowest step; the first patient is enrolled, then, months or years later, the last. Throughout, the data monitoring committee reviews unblinded data at pre-planned interim analyses, monitors verify the data at sites, and safety reports flow to regulators and ethics committees.

Readout is event-driven for survival endpoints: the protocol names the number of deaths or progressions that trigger the primary analysis, the database is locked at a data cut-off date, the statisticians run the pre-specified analysis, and the sponsor announces the topline result, usually in a press release within weeks, followed by a congress presentation (ASCO, ESMO, ASH and their kin) and a peer-reviewed paper. If the result supports a new use, the sponsor files with regulators; the review takes months (with priority review and accelerated approval shortening it in the United States, and conditional marketing authorisation in Europe), an advisory committee may be convened, and approval adds the indication to the drug's label. Guidelines update, payers decide whether to reimburse, and the trial continues to follow patients for overall survival and late toxicity, sometimes for a decade, while a confirmatory or post-marketing trial may be required.

The corpus lets a reader follow the whole arc. KEYNOTE-522 was registered as NCT03036488, read out on pathological complete response, then event-free and overall survival, and led to approval of neoadjuvant pembrolizumab in triple-negative breast cancer. ADAURA was unblinded early by its monitoring committee, published in 2020, approved the same year and confirmed on survival in 2023. NAVIGATE's basket result became a tumour-agnostic label in 2018. ANNOUNCE and ATLANTIS show the lifecycle in reverse: accelerated approvals on early data, confirmatory trials that failed, and in olaratumab's case a withdrawal. The regulatory timeline page dates every filing, approval and label change in the corpus, and the catalyst calendar lists the readouts and decisions still to come.